Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neoplasm Metastasis 5Colorectal Neoplasms 5Pancreatic Neoplasms 4Sarcoma 3Insulin-Like Growth Factor I, Resistance To 3Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Adenocarcinoma 2Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Pleural Effusion, Malignant 1Neuroectodermal Tumors, Primitive 1Melanoma 1Lymphoma 1Lung Neoplasms 1Jaundice 1Gastrointestinal Neoplasms 1Endocrine Gland Neoplasms 1Carcinoid Tumor 1Askin Tumor 1

Interventions

Gemcitabine 22Fluorouracil 14Oxaliplatin 13Capecitabine 13Paclitaxel 12pembrolizumab 11Cisplatin 11Carboplatin 11Pemetrexed 10Leucovorin 9130-nm albumin-bound paclitaxel 9Ramucirumab 8zolbetuximab 7Albumin-Bound Paclitaxel 7trastuzumab deruxtecan 6Drug Therapy 5Docetaxel 5Bevacizumab 5Nivolumab 4Irinotecan 4vandetanib 3cemiplimab 3Everolimus 3EC145 3tislelizumab 2technetium 99m etarfolatide 2spartalizumab 2pralsetinib 2osimertinib 2nimotuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma × ganitumab × Clear all
NCT01318642 2024-11-08

Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

NantBioScience, Inc.

Phase 2 Terminated
10 enrolled 10 charts
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT00813605 2016-10-27

QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma

NantCell, Inc.

Phase 2 Completed
155 enrolled
Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡